170 related articles for article (PubMed ID: 29311298)
21. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
[TBL] [Abstract][Full Text] [Related]
22. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
23. IκB kinase α functions as a tumor suppressor in epithelial-derived tumors through an NF-κB-independent pathway (Review).
Xie Y; Xie K; Gou Q; Chen N
Oncol Rep; 2015 Nov; 34(5):2225-32. PubMed ID: 26323241
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of lipocalin 2 suppresses the growth of human lung adenocarcinoma through oxidative stress involving Nrf2/HO-1 signaling.
Song B; Zhang H; Jiang L; Chi Y; Tian J; Du W; Yu B; Han Z
Acta Biochim Biophys Sin (Shanghai); 2015 Oct; 47(10):805-14. PubMed ID: 26350099
[TBL] [Abstract][Full Text] [Related]
25. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
26. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
27. COL5A1 may contribute the metastasis of lung adenocarcinoma.
Liu W; Wei H; Gao Z; Chen G; Liu Y; Gao X; Bai G; He S; Liu T; Xu W; Yang X; Jiao J; Xiao J
Gene; 2018 Jul; 665():57-66. PubMed ID: 29702185
[TBL] [Abstract][Full Text] [Related]
28. USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity.
Li J; Wang Y; Luo Y; Liu Y; Yi Y; Li J; Pan Y; Li W; You W; Hu Q; Zhao Z; Zhang Y; Cao Y; Zhang L; Yuan J; Xiao ZJ
Nat Commun; 2022 Dec; 13(1):7799. PubMed ID: 36528652
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
30. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase C delta activates IkappaB-kinase alpha to induce the p53 tumor suppressor in response to oxidative stress.
Yamaguchi T; Miki Y; Yoshida K
Cell Signal; 2007 Oct; 19(10):2088-97. PubMed ID: 17644309
[TBL] [Abstract][Full Text] [Related]
32. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.
Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M
Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
Tan M; Li H; Sun Y
Neoplasia; 2015 Jan; 17(1):114-23. PubMed ID: 25622904
[TBL] [Abstract][Full Text] [Related]
34. Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species.
Kasiri S; Chen B; Wilson AN; Reczek A; Mazambani S; Gadhvi J; Noel E; Marriam U; Mino B; Lu W; Girard L; Solis LM; Luby-Phelps K; Bishop J; Kim JW; Kim J
Oncogene; 2020 Apr; 39(16):3258-3275. PubMed ID: 32108165
[TBL] [Abstract][Full Text] [Related]
35. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
36. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
37. KRAS G12D mutation eliminates reactive oxygen species through the Nrf2/CSE/H
Fan K; Zhang S; Ni X; Shen S; Wang J; Sun W; Suo T; Liu H; Ni X; Liu H
Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 54(11):1731-1739. PubMed ID: 36514219
[TBL] [Abstract][Full Text] [Related]
38. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.
Li F; Han X; Li F; Wang R; Wang H; Gao Y; Wang X; Fang Z; Zhang W; Yao S; Tong X; Wang Y; Feng Y; Sun Y; Li Y; Wong KK; Zhai Q; Chen H; Ji H
Cancer Cell; 2015 May; 27(5):698-711. PubMed ID: 25936644
[TBL] [Abstract][Full Text] [Related]
39. Interferon-gamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells.
Kim KS; Kang KW; Seu YB; Baek SH; Kim JR
Mech Ageing Dev; 2009 Mar; 130(3):179-88. PubMed ID: 19071156
[TBL] [Abstract][Full Text] [Related]
40. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
